Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR 180.81
+12.54 (7.45%)
Mar 10, 2026, 11:00 AM IST
Jagsonpal Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Net Income | - | 553.61 | 224.63 | 267.21 | 188.55 | 170.58 | Upgrade
|
| Depreciation & Amortization | - | 81.31 | 16.63 | 11.75 | 15.26 | 10.86 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -233.59 | - | -3.59 | -0.85 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 1.75 | - | 28.09 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -1.48 | -11.36 | 2.51 | Upgrade
|
| Stock-Based Compensation | - | 68.04 | 133.1 | 87.65 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 7.67 | 2.62 | 0.42 | - | Upgrade
|
| Other Operating Activities | - | 26.64 | -85.76 | -20.66 | -8.33 | -17.67 | Upgrade
|
| Change in Accounts Receivable | - | -22.25 | 91.54 | -55.56 | -29.55 | 87.89 | Upgrade
|
| Change in Inventory | - | 0.01 | 53.1 | 86.86 | -0.18 | -4 | Upgrade
|
| Change in Accounts Payable | - | 21.38 | -89.82 | -19.62 | -10.75 | 63.41 | Upgrade
|
| Change in Income Taxes | - | - | - | - | - | -92.92 | Upgrade
|
| Change in Other Net Operating Assets | - | 56.1 | 0.57 | 83.28 | -74.07 | -57.92 | Upgrade
|
| Operating Cash Flow | - | 553 | 351.66 | 466.55 | 69.14 | 282.22 | Upgrade
|
| Operating Cash Flow Growth | - | 57.25% | -24.63% | 574.79% | -75.50% | 137.46% | Upgrade
|
| Capital Expenditures | - | -3.48 | -2.48 | -3.18 | -10.49 | -4.69 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 357.18 | - | 12.96 | 5.81 | - | Upgrade
|
| Cash Acquisitions | - | -936.57 | - | - | - | - | Upgrade
|
| Investment in Securities | - | 53 | -316.67 | -620.77 | -268.57 | -41.73 | Upgrade
|
| Other Investing Activities | - | 78.4 | 73.67 | 34.28 | 15.46 | 23.78 | Upgrade
|
| Investing Cash Flow | - | -451.47 | -245.48 | -576.71 | -257.79 | -22.64 | Upgrade
|
| Long-Term Debt Repaid | - | -9.02 | -6.33 | -0.44 | -67.88 | - | Upgrade
|
| Total Debt Repaid | - | -9.02 | -6.33 | -0.44 | -67.88 | - | Upgrade
|
| Net Debt Issued (Repaid) | - | -9.02 | -6.33 | -0.44 | -67.88 | - | Upgrade
|
| Issuance of Common Stock | - | 33.91 | 56.35 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -36.95 | Upgrade
|
| Common Dividends Paid | - | -132.29 | -130.99 | - | -104.79 | -26.2 | Upgrade
|
| Other Financing Activities | - | -9.58 | -8.14 | -4.13 | -2.85 | -5.14 | Upgrade
|
| Financing Cash Flow | - | -116.98 | -89.11 | -4.57 | -175.52 | -68.28 | Upgrade
|
| Net Cash Flow | - | -15.45 | 17.07 | -114.73 | -364.17 | 191.3 | Upgrade
|
| Free Cash Flow | - | 549.52 | 349.18 | 463.37 | 58.65 | 277.53 | Upgrade
|
| Free Cash Flow Growth | - | 57.37% | -24.64% | 690.06% | -78.87% | 176.69% | Upgrade
|
| Free Cash Flow Margin | - | 20.45% | 16.73% | 19.57% | 2.70% | 14.77% | Upgrade
|
| Free Cash Flow Per Share | - | 8.16 | 5.27 | 7.08 | 0.90 | 4.24 | Upgrade
|
| Cash Interest Paid | - | 8.58 | 7.77 | - | 2.61 | 4.28 | Upgrade
|
| Cash Income Tax Paid | - | 81.43 | 85.13 | 72.76 | 68.73 | 31.5 | Upgrade
|
| Levered Free Cash Flow | - | 638.24 | 197.59 | 425.62 | 49.28 | 157.46 | Upgrade
|
| Unlevered Free Cash Flow | - | 643.61 | 202.44 | 427.36 | 50.92 | 160.13 | Upgrade
|
| Change in Working Capital | - | 55.24 | 55.39 | 94.96 | -114.55 | 115.94 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.